All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for ELI LILLY & COMPANY · Pharmaceutical/ Health Products

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 1

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 6

Taxation/Internal Revenue Code

International and domestic tax issues. OBBB.

Health Issues

General education about policies impacting pharmaceutical development and approval. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention, 340B Program. Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN.

Medicare/Medicaid

Policies impacting Medicare Part D and Part B reimbursement policies. "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. HR. 1, One Big Beautiful Bill Act, MFN drug pricing proposals.

Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Trade (domestic/foreign)

Issues related to pharmaceutical manufacturing and development. Tariffs.

Defense

Issues related to pharmaceutical manufacturing and development.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.